AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT05933668 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: YK0901 cells
Description: On day 0, the TCR-T cells will be administered one time. Drug: Fludarabine + Cyclophosphamide+Oxaliplatin Fludarabine: 25mg/m²/day×3days Cyclophosphamide: 300mg/m²/day×3 days Oxaliplatin：100mg×1day Drug: IL-2 After 18-24 hours of infusion of YK0901 cells, the patients will be given a small dose of IL-2 subcutaneously, 500,000 IU/time, twice a day (interval 10-12 hours), for 14 days.
Study NCT05240001 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Thulium Fibre Laser
Description: Participants will undergo treatment using the TFL
Study NCT05240001 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MOSES Holmium Laser
Description: Participants will undergo treatment using the MOSES Holmium laser.
Study NCT06038734 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: gastric ultrasound
Description: Utilize POC gastric ultrasound to identify the presence of retained gastric contents.
Study NCT06584305 — intervention group
Intervention type: PROCEDURE
Intervention: AI-Powered Body Dysmorphic Disorder Screening Procedure
Description: The AI-Powered Body Dysmorphic Disorder Screening Procedure involves using an AI tool to evaluate patients for Body Dysmorphic Disorder (BDD) before undergoing elective cosmetic surgery. The screening integrates the Body Dysmorphic Disorder Questionnaire (BDDQ) with additional psychological assessments. The AI system processes the collected data to produce a risk score, guiding surgeons in making informed decisions about the need for psychological evaluation or intervention, and determining the suitability of patients for surgery.
Study NCT06205082 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LIT-00814
Description: LIT-00814 is an oral tablet.
Study NCT04625764 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Blood sampling and analysis
Description: Blood sampling for pharmacokinetics (Plasma ticagrelor concentrations and its metabolite) and MEA platform testing (ADPtest, TRAPtest)
Study NCT04091243 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Romosozumab
Description: Experimental drug for the treatment of glucocorticoid induced osteoporosis
Study NCT04091243 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Romosozumab
Description: Experimental drug for the treatment of glucocorticoid induced osteoporosis
Study NCT05985967 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PBMT-sMF
Description: PBMT-sMF applied in the lower limbs with different doses per muscle group.
Study NCT05985967 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Shock wave
Description: Shock wave therapy applied in the lower limbs for 30 minutes.
Study NCT05985967 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Pneumatic compression
Description: Pneumatic compression applied in the lower limbs for 30 minutes.
Study NCT06721468 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Child-centered nutrition phrases
Description: learn the phrase, trout helps your brain so you can learn and play either through researcher introduction or completing the About Trout! Pond to Plate curriculum
Study NCT05985967 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Passive recovery
Description: Volunteers laid in supine position resting for 30 minutes.
Study NCT04565795 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Uriprene® Degradable Temporary Ureteral Stent
Description: Assess adequate intervention-free drainage during use and the time to complete degradation or the passage of stent fragments/segments from the urinary system by radiological assessment.
Study NCT06168617 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Performance tasks in daily life
Description: Evaluation of performance tests executed by patients in real-life situations.
Study NCT05863637 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Intensive Short-Term Dynamic Psychotherapy
Description: A dynamic and intensive psychotherapy with eight therapeutic sessions
Study NCT05334901 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: High intensity light cure
Description: Bulk fill resin composite restoration cured with high intensity light curing (2200 mw/cm2)To achieve increased power and a wider spectrum for short exposure time (1 second) to overcome resin composite restoration techniques sensitivity and shorten the clinical procedure
Study NCT05334901 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: High intensity light cure
Description: Bulk fill resin composite restoration cured with high intensity light curing (2200 mw/cm2)To achieve increased power and a wider spectrum for short exposure time (1 second) to overcome resin composite restoration techniques sensitivity and shorten the clinical procedure
Study NCT04877938 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Echolgical physical activity Intervention
Description: 'Ecological-Exercise-Intervention'(EEI), would be to limit sitting time to no more than 2 hours/day, and to stand up and move after 30 minutes of continuous sitting. In accordance with several epidemiologic evidences light-intensity activities would be encouraged to substitute sedentary time (e.g., standing up while talking on the telephone, ironing while watching TV).
Study NCT04877938 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Echolgical physical activity Intervention
Description: 'Ecological-Exercise-Intervention'(EEI), would be to limit sitting time to no more than 2 hours/day, and to stand up and move after 30 minutes of continuous sitting. In accordance with several epidemiologic evidences light-intensity activities would be encouraged to substitute sedentary time (e.g., standing up while talking on the telephone, ironing while watching TV).
Study NCT06721468 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Puzzle
Description: presented with a puzzle to solve each week
Study NCT05788497 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hemorrane plus
Description: Hemorrane 10 mg/g rectal ointment + 30 mg/g benzocaine
Study NCT05788497 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Hemorrane
Description: Hemorrane 10 mg/g rectal ointment
Study NCT06067295 — intervention group
Intervention type: OTHER
Intervention: Non-Interventional Study
Description: Non-interventional study
Study NCT04856293 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Crizotinib
Description: A single 250 mg crizotinib dose of the FC formulation
Study NCT04856293 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Crizotinib
Description: A single 250 mg crizotinib dose of the encapsulated microsphere (eMS) formulation administered by sprinkling the contents into a dry glass vial
Study NCT04856293 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Crizotinib
Description: A single 250 mg crizotinib dose of the single 250 mg crizotinib dose of the encapsulated microsphere (eMS) formulation (administered as intact capsules) . The intact capsules will be swallowed whole.
Study NCT05961761 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Propranolol
Description: propranolol 40 mg x2 daily
Study NCT05961761 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: pembrolizumab 2 mg/kg every 3 weeks
Study NCT04650932 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Deep brain stimulation
Description: Patients with idiopathic Parkinson's disease who have previously been implanted with the Boston Scientific VerciseTM DBS system for at least 3 months. These patients will already be receiving high-frequency dorsal STN stimulation as part of the standard of care for PD. Once patients have provided consent and are enrolled in this study, they will receive simultaneous low-frequency stimulation of the ventral STN to examine if there are any effects on cognitive performance.
Study NCT05686967 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: MitoQ
Description: MitoQ is a biochemically modified form of ubiquinol
Study NCT05686967 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Each placebo capsule contains inert excipient and is identical in appearance
Study NCT05788497 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Rectal ointment
Study NCT01796795 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Vehicle gel
Description: Topical application on the target lesion(s)once daily with occlusive dressing; a maximum of 3 times of administration of gel without exceeding 0.2 g per administration.
Study NCT01796795 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: SR-T100 gel with 1.0% of SM
Description: Topical application on the target lesion(s)once daily with occlusive dressing; a maximum of 3 times of administration of gel without exceeding 0.2 g per administration.
Study NCT01796795 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: SR-T100 gel with 2.3% of SM
Description: Topical application on the target lesion(s)once daily with occlusive dressing; a maximum of 3 times of administration of gel without exceeding 0.2 g per administration.
Study NCT05061628 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JS006 as Monotherapy
Description: 1. JS006 as Monotherapy dose-escalation: JS006, 18/ 60/ 180/ 600/ 1800mg, IV infusion, every 3 weeks (q3w).~2. JS006 as Monotherapy dose-extension: JS006, 1 or 2 specific dose, IV infusion, every 3 weeks (q3w).
Study NCT05061628 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JS006 in combination with Toripalimab
Description: 1. JS006 in combination with Toripalimab dose-escalation: JS006, 2 or 3 specific dose, IV infusion, every 3 weeks (q3w), combined with Toripalimab, 240mg, IV infusion, every 3 weeks (q3w).~2. JS006 in combination with Toripalimab dose-extension: JS006, 1 or 2 specific dose, IV infusion, every 3 weeks (q3w), combined with Toripalimab, 240mg, IV infusion, every 3 weeks (q3w).~3. JS006 in combination with Toripalimab indications expansion: JS006, RP2D, IV infusion, every 3 weeks(q3w), combined with Toripalimab, 240mg, IV infusion, every 3 weeks (q3w).
Study NCT04738773 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Naltrexone
Description: On the active drug group, naltrexone will be prescribed on flexible dose mode, receiving 50mg per day on the first week, with an increase of 25mg each week until a maximum of 200 mg per day or as much as tolerated by the patient.
Study NCT04738773 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study NCT06340438 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Histamine
Description: Histaminergic itch will be evoked by a 1% histamine solution. A droplet of histamine solution will be placed on the predetermined area on the forearm, and the SPT lancet will be pierced through the histamine with 120 g of pressure for 1-2 seconds.
Study NCT06340438 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Cowhage
Description: 25 spicules will be inserted in the center of the predefined skin area on the mandibular area. The spicules will be gently rubbed for 15-20 seconds in circular motion to facilitate epidermal penetration.
Study NCT05963087 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cetuximab Dabrafenib Tislelizumab
Description: Dabrafenib 150mg，BID, Cetuximab 250mg/m2, Tislelizumab 200mg Treatment every three weeks
Study NCT05383079 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lutetium-177 PSMA-I&T
Description: Patients will be given 7.4 GBq of 177Lu-PSMA every 6 weeks for up to 6 Cycles
Study NCT05383079 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Radium-223
Description: During dose escalation, doses of Radium-223 that will be administered include 27.5 kBq/kg and 55 kBq/kg. The maximum tolerated dose of Radium-223 will be used during dose expansion. Radium-223 will be given once every 6 weeks for up to 6 doses between day 1-5 of each Cycle.
Study NCT05602415 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anlotinib
Description: Anlotinib of 12mg will be administered orally, once daily, 2-days on/1-day off, until disease progression according to RECIST 1.1, death, unacceptable toxicity, or withdrawal of consent for any reasons. A cycle was considered to be 3 weeks. Anlotinib should be started 3-4 weeks after surgery, and continued for 3 months (4 cycles). The dose could be reduced to 8-10 mg once daily for patients who had grade 3 or 4 treatment-related toxicities, or for patients with intolerable grade 2 toxicity, despite maximum supportive care measures. If dose reduction was necessary, then the dose of anlotinib was reduced to 10 mg once daily. If further dose reduction was necessary, the dosage was reduced to 8 mg once daily. If the dosage of 8 mg once daily was not tolerable, then the patient stopped receiving anlotinib.
Study NCT05602415 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiotherapy
Description: Postoperative radiotherapy would be performed. Postoperative intensity-modu¬lated RT (IMRT) will be performed (50 Gy in 2.0 Gy per fraction). No boost dose would be added if the margin was negative, a boost dose of 10-16 Gy would be added if the margin was microscopically positive, and a boost dose of 16-18 would be added if the margin was gross positive.
Study NCT05602415 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Surgery
Description: Surgery
Study NCT05686967 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Aerobic exercise
Description: Moderate intensity aerobic exercise on the treadmill
Study NCT05686967 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Aerobic exercise
Description: Moderate intensity aerobic exercise on the treadmill
Study NCT05902039 — intervention group
Intervention type: OTHER
Intervention: MRI
Description: All participants underwent an MR examination on a 3T whole-body Prisma MRI system (Siemens, Erlangen, Germany) with a 64-channel head coil, and a 7T whole-body MAGNETOM MR system (Siemens, Erlangen, Germany) using a 32-channel receive/birdcage transmit head coil (NOVA medical). DP-pCASL, Multi-delay pCASL (MD-pCASL) was acquired to evaluate BBB function and cerebral perfusion. T1-weighted magnetization-prepared rapid gradient echo (T1w-MPRAGE) was scanned at both 3T and 7T for registration in the post-processing workflow. T2-weighted fluid-attenuated inversion recovery (T2w-FLAIR) and T2\*-weighted gradient echo (T2\*w-GRE) were acquired at 7T for high-resolution structural images and evaluation of lesions.
Study NCT05868070 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Conventional rehabilitation plus multimodal exercise
Description: Depending on the patient's condition, the intervention gradually progressed to passive, active assistive, active, and resistive exercise modes and the frequency of exercise interventions is gradually increased, and the application time of cycling/stepping is 20 minutes per session, and up to 3 times if there is no serious problem corresponding to the safety standards.
Study NCT04190134 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Socially Assistive Robot for Low Vision Rehabilitation
Description: A socially assistive robot will be customized to engage in dialog and conversations to motivate and encourage optimal use of new magnification devices for reading at home by individuals with vision loss.
Study NCT04190134 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Socially Assistive Robot for Low Vision Rehabilitation
Description: A socially assistive robot will be customized to engage in dialog and conversations to motivate and encourage optimal use of new magnification devices for reading at home by individuals with vision loss.
Study NCT06332716 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Based on diagnostic and treatment guidelines/expert consensus, as well as clinical treatment experience, it is recommended that no more than 9 drugs be used for drug sensitivity testing each time.
Description: Based on diagnostic and treatment guidelines/expert consensus, as well as clinical treatment experience, it is recommended that no more than 9 drugs be used for drug sensitivity testing each time. The sending doctor can choose from the following relevant treatment drugs and confirm with the responsible researcher for drug sensitivity testing.
Study NCT06332716 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Based on diagnostic and treatment guidelines/expert consensus, as well as clinical treatment experience, it is recommended that no more than 9 drugs be used for drug sensitivity testing each time.
Description: Based on diagnostic and treatment guidelines/expert consensus, as well as clinical treatment experience, it is recommended that no more than 9 drugs be used for drug sensitivity testing each time. The sending doctor can choose from the following relevant treatment drugs and confirm with the responsible researcher for drug sensitivity testing.
Study NCT04210141 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: lyophilized BPI viper antivenom
Description: Antivenom
Study NCT04210141 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: lyophilized BPI viper antivenom
Description: Antivenom
Study NCT05943548 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Omuyambi
Description: HIV testing, referral, care linkage, and medication adherence support
Study NCT05943548 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Control
Description: HIV Testing and referral
Study NCT04033718 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Inpatient lab bundling
Description: The investigators will provide patients a package of diagnostic tests at the time of admission to comprehensively assess for HIV coinfections and treatment failure. These labs are all recommended in advanced HIV guidelines but in this study we will provide all tests as a bundle rather than step-by-step as suggested in guidelines.
Study NCT04033718 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Inpatient navigation
Description: Participants will be assigned a patient navigator who will support the patient and bedsider (treatment supporter/guardian) during the hospitalization. The navigator will be an HIV counselor who can provide counseling and health education, as well as support specimen transport, obtaining results, booking tests in other departments, linkages to ART clinic, and discharge planning
Study NCT06025630 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TUDCA
Description: Endoplasmic reticulum stress will be inhibited by chronic (8 weeks) oral ingestion of the dietary supplement tauroursodeoxycholic acid (TUDCA; 1,750 mg/day)
Study NCT06025630 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo pills containing microcrystalline cellulose will be ingested over the course of the 8 week intervention.
Study NCT05222516 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Broncho-Vaxom
Description: Daily administration of Broncho-Vaxom 3.5mg capsules
Study NCT05222516 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Daily administration of Placebo capsules
Study NCT04996979 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ropivacaine 0.5% Injectable Solution
Description: Local anaesthetic solution composed of ropivacaine 0.5%(intervention group)
Study NCT04996979 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Standard care
Study NCT05890105 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-07853578
Description: PF-07853578 will be administered as oral solutions or suspensions as escalating single doses to be determined.
Study NCT05890105 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo will be administered as oral solutions or suspensions as escalating single doses to be determined.
Study NCT05898789 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: CaRE@Home intervention
Description: participants randomized to the intervention arm will complete a virtual 8 week exercise and education program.
Study NCT00749827 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bicarbonate Hydration
Description: Intravenous sodium bicarbonate (130 mEq/L) in 4.35% dextrose at 3.5 ml/Kg over 1 hour pre-contrast, followed by the same solution intravenously at 1 ml/Kg/hr for 6 hours. In all cases the maximum rate of fluid permitted is that for a body weight of 110 Kg. Intra-vascular low-osmolal or iso-osmolal contrast (according to operator or institution choice) will be used in the minimal dose needed to complete the required imaging.~Hypotonic hydration arm. Intravenous 5% dextrose in water at 3.5 ml/Kg over 1 hour pre-contrast followed by 0.9% saline intravenously at 1 ml/Kg/hr for 6 hours.
Study NCT05406869 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Pulsed Sonic Balloon Dilatation Catheter and Pulsed Sonic Generater
Description: Deliver Pulsed Sonic Balloon Dilatation Catheter to the target vessel prior to placing a coronary stent or others
Study NCT04940884 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Supervised exercise training
Description: SET Participants underwent 24 sessions of moderate-intensity exercise training (MICT) at 70% maximum predicted heart rate for 30 min in each session
Study NCT04940884 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Aerobic exercise training
Description: All recruited subjects were instructed to walk >=8000 steps per day in the community. Part of the participants were randomly assigned to underwent additional 24 sessions of supervised aerobic exercise training (SET) with the intensity at 70% of maximum predicted heart rate and the remaining participants follow the above home exercise training (HET) instruction without additional supervised exercise training.